Kriangkrai Tawinprai

Bangkok, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Post-exposure prophylaxis with favipiravir among household close contacts to confirmed COVID-19 cases: A cluster-randomized trial (PEPfavi).

Post-exposure prophylaxis with favipiravir among household close contacts to confirmed COVID-19 cases: A cluster-randomized trial (PEPfavi).

Journal: Journal of infection and public health

Published: July 14, 2025

Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev).

Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev).

Journal: Journal of virus eradication

Published: October 24, 2024

Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer.

Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer.

Journal: JCO global oncology

Published: May 23, 2024

Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST).

Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST).

Journal: Journal of infection and public health

Published: January 19, 2024

A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV).

A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV).

Journal: Journal of infection and public health

Published: November 20, 2023

Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab).

Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab).

Journal: Microbiology spectrum

Published: November 17, 2023

The existence of adrenal insufficiency in patients with COVID-19 pneumonia.

The existence of adrenal insufficiency in patients with COVID-19 pneumonia.

Journal: Frontiers in endocrinology

Published: November 13, 2023

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study.

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study.

Journal: Human vaccines & immunotherapeutics

Published: September 06, 2023

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.

Journal: Scientific reports

Published: May 18, 2023

The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.

The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.

Journal: Medicina (Kaunas, Lithuania)

Published: May 05, 2023

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.

Journal: Human vaccines & immunotherapeutics

Published: May 04, 2023

Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV).

Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV).

Journal: Scientific reports

Published: April 23, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026